Filing Flows › Comparisons › IRMD vs LUNG
Iradimed vs Pulmonx: IRMD and LUNG compared
Iradimed is the larger company: $24.2M of revenue in its latest quarter (Q3 2026) against $22.8M for Pulmonx (Q3 2026). Iradimed is growing faster (+14% against +6% a year earlier). Iradimed is more profitable, with an operating margin of 33.6% against -32.8%.
Where the money goes: IRMD and LUNG
Iradimed (IRMD) · Q3 2026
Iradimed, Q3 2026: revenue $24.2M (+14% year over year), operating margin 33.6%, net earnings $6.5M, operating cash flow $7.0M. The chart follows the revenue to costs, profit and cash.
Pulmonx (LUNG) · Q3 2026
Pulmonx, Q3 2026: revenue $22.8M (+6% year over year), operating margin -32.8%, net loss $8.4M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
| Iradimed (IRMD) | Pulmonx (LUNG) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $24.2M | $22.8M |
| Revenue growth, Y/Y | +14% | +6% |
| Gross margin | 76.3% | — |
| Operating margin | 33.6% | -32.8% |
| Net earnings | $6.5M | −$8.4M |
| Net margin | 26.9% | -36.8% |
| Operating cash flow | $7.0M | −$3.2M |
| Free cash flow | $6.8M | — |
| Market value | $1.1B | — |
| P/E | 46.8× | — |
| Analysts’ mean target | $118.00 | — |
Where the revenue comes from
Iradimed
- Total devices revenue: $17.2M (71%)
- Disposables: $5.0M (21%)
- Services and other: $1.2M (5%)
- Amortized Revenue: $801K (3%)
Questions
Which is bigger, Iradimed or Pulmonx?
Iradimed is the larger company: $24.2M of revenue in its latest quarter (Q3 2026) against $22.8M for Pulmonx (Q3 2026).
Is Iradimed or Pulmonx growing faster?
Iradimed is growing faster (+14% against +6% a year earlier).
Which is more profitable, Iradimed or Pulmonx?
Iradimed is more profitable, with an operating margin of 33.6% against -32.8%.
More: Iradimed earnings · how Iradimed makes money · Pulmonx earnings · how Pulmonx makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 30, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.